# Task 1 Preference Label - Transcript A vs B (workspace backup)

Stage: Step 15 Preference Labeling (Healthcare_247_Merrow Task 1, batch 20260606_163720).
Current status: historical backup. Preference Labeling, downstream checks, and final human review are now complete.
Studio-selected pair:
- Transcript A = 0.900 (run a9881c8c-a572-4ab4-bcf9-591a5e7cff3f), 40 steps, 8 pages.
- Transcript B = 0.970 (run a1c6c072-2e61-436b-b6c2-aa74e0861677), 33 steps.
Both deliverables read in full against golden-response-task1-v6.docx before labeling.

KEY FINDING (verified from both shipped docs, not build logs): both attempts are clinically correct on every high-risk decision and neither falls for a planted trap. Both decline the nitrofurantoin switch and keep cefpodoxime, both decline the potassium salt substitute as a hyperkalemia hazard, both defer the home-dose sacubitril/valsartan restart to staged outpatient sequencing, both keep all held cardiorenal agents (neither drops metformin), neither fabricates a culture result, and BOTH correctly refuse to write prednisone 5 mg as a verified dose (A bridges at the interim inpatient dose and says "do not assert 5 mg daily"; B says "does not confirm that dose" and defers the number to rheumatology). Prednisone is NOT the differentiator here - that was the 0.78 run in the FA, a different trajectory. The gap is polish/clarity only; no clinical-correctness gap and no error in A.

VERDICT: B1 (B slightly better). Button = plain "B" (no plus signs). NOT B+ (that is B2 and would overstate the gap).

## Justification (LABELED form per the appendix PL EXAMPLE in the Project Sanctum Instruction Doc - PL uses the dimension labels as section headers and ENDS with a Summary section. This is the OPPOSITE of FA/GA, which is header-free prose. Do not strip these labels.)

Preferred output: B

B is slightly preferred over A. Both attempts are clinically correct on every high-risk decision and neither falls for a planted trap, so the gap is narrow and comes down to clarity and fit rather than safety. Both decline the nitrofurantoin switch and continue cefpodoxime, both decline the potassium-based salt substitute as an exogenous potassium load, both defer the home-dose sacubitril/valsartan restart to a staged outpatient pathway, and both treat the prednisone home dose as unverified and decline to write 5 mg daily off the most recent fill. B edges ahead on the discipline of the write-up and one concrete steroid-safety step, not on catching anything A missed.

Justification: The decision comes down to how cleanly each handles the contested items and how usable the final note is at the bedside. B frames the prednisone disposition more crisply, stating plainly that the reconciliation does not confirm the dose and deferring the numeric taper to rheumatology, and adds the concrete step of having the family quarantine the older prednisone bottles with conflicting taper directions. A reaches the same correct dispositions through a more discursive note and a less direct partially-adopt framing on prednisone. There is no clinical error in either attempt and no correctness win for either side; the difference is fit-for-purpose, not clinical adequacy.

Prompt adherence: Both deliver what the prompt asked, a disposition-organized reconciliation co-signable by pharmacy and the hospitalist that addresses each pharmacy handoff recommendation point by point and includes the discharge antibiotic rather than only the chronic medications. Both respond to all of pharmacy's recommendations and neither omits the antibiotic. This dimension is a tie.

Correctness: Both are accurate against the chart and reach the same safe conclusions. Both decline nitrofurantoin and continue cefpodoxime, citing the systemic urinary source and the eGFR of 40 to 50; both decline the salt substitute as a potassium load given CKD stage 3 and the pending cardiorenal restarts; both defer the sacubitril/valsartan restart consistent with nephrology; and both correctly leave the prednisone home dose unverified rather than writing 5 mg. Neither asserts adrenal insufficiency as proven and neither fabricates a culture result. I did not find a clinical error in either attempt.

Completeness: Both cover the full reconciliation, keep all held cardiorenal agents on the list with reassessment plans rather than dropping any, keep inpatient correctional lispro out of the home regimen, and turn the documented functional and medication-management risk into a follow-up plan. B is slightly more complete on the steroid-safety margin with the bottle-quarantine step. A is more discursive in the narrative and adds more counseling detail. No material finding is missing from either.

Methodology: Both work from the chart rather than the handoff and adjudicate each recommendation against the record. A reasons sharply that the potassium improvement was achieved while the potassium-sparing agents were held and so is not evidence they can be restarted safely, which is a genuine strength. B is marginally cleaner in treating the consultants' positions as the closing dispositions and in framing the prednisone decision. The approaches are equally sound; the difference is presentation.

Quality and clarity: This is what decides it. Both are well organized and physician-facing, but B reads as the tighter, more directly co-signable note, with cleaner disposition language on the contested items, while A, though equally correct, is more verbose and frames the prednisone decision less crisply. For a covering hospitalist signing at the bedside, B is marginally easier to act on.

Summary: B is preferred because it is the cleaner, more directly co-signable version of an answer that is clinically equivalent to A, with crisper disposition language on the contested items and one concrete steroid-safety step A lacks. A is fully senior-reviewer-acceptable on the clinical content; the difference is clarity and fit, not clinical adequacy, which is why this is a slightly-better B1 rather than a wider gap.

## Guardrails (must survive any edit)
1. No sentence names a clinical error in A (there is none).
2. Prednisone stated as handled correctly by BOTH (do not reuse the FA's prednisone-failure framing; that was the 0.78 run).
3. Strongest word for the gap stays "marginally" / "slightly" - this is B1, not B2.

## Submit mechanics
Historical submit mechanics: select plain B -> paste justification into Comments -> Submit Preference -> confirm entry shows in submission history -> run Preference Labels AutoQC. This sequence is complete; this file is preserved as the workspace backup.
